Rationally Designed Enzyme-Resistant Peptidic Assemblies for Plasma Membrane Targeting in Cancer Treatment

Area of Science:

• Biotechnology
• Nanomedicine
• Cancer Research

Background:

• Peptides are crucial for targeted cancer therapies, aiming to enhance specificity and overcome multidrug resistance.
• Targeting the plasma membrane (PM) with self-assembling peptides remains an underexplored area in cancer treatment strategies.

Purpose of the Study:

• To develop a novel, enzyme-resistant, self-assembling peptide for targeting the cancer cell plasma membrane (PM).
• To investigate the mechanism by which the peptide assemblies interact with the PM and induce cancer cell death.

Main Methods:

• Synthesis and characterization of a novel peptidic molecule (tF4).
• Investigation of tF4 self-assembly into vesical nanostructures.
• Analysis of tF4 assembly interaction with the plasma membrane (PM) via hydrogen bonding and hydrophobic interactions.
• Evaluation of tF4-induced cellular changes, including cytoskeleton remodeling and death receptor expression.

Main Results:

• The synthetic peptide tF4 demonstrated resistance to carboxyl esterase.
• tF4 self-assembled into nanostructures that interact with the cancer cell PM.
• tF4 assemblies induced stress fiber formation, cytoskeleton reconstruction, and increased expression of death receptors (DR4/5).
• Upregulation of DR4/5 triggered the extrinsic caspase-8 signaling pathway, leading to cancer cell death.

Conclusions:

• A new strategy using enzyme-resistant, PM-targeting self-assembling peptides for cancer therapy has been established.
• tF4 represents a promising candidate for developing novel peptide-based cancer treatments.
• The findings highlight the potential of modulating cellular functions and death receptor pathways via PM-targeted nanostructures.